Masimo Co. (NASDAQ:MASI) Forecasted to Post Q4 2023 Earnings of $0.91 Per Share

Masimo Co. (NASDAQ:MASIFree Report) – Zacks Research issued their Q4 2023 earnings per share estimates for Masimo in a research note issued to investors on Thursday, February 1st. Zacks Research analyst I. Bandyopadhyay anticipates that the medical equipment provider will post earnings per share of $0.91 for the quarter. The consensus estimate for Masimo’s current full-year earnings is $3.50 per share. Zacks Research also issued estimates for Masimo’s Q1 2024 earnings at $0.74 EPS, Q2 2024 earnings at $0.91 EPS, Q3 2024 earnings at $0.79 EPS, Q4 2024 earnings at $0.87 EPS, FY2024 earnings at $3.31 EPS, Q1 2025 earnings at $0.73 EPS, Q2 2025 earnings at $0.83 EPS, Q3 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.14 EPS and FY2025 earnings at $3.67 EPS.

Several other research analysts have also recently issued reports on the company. StockNews.com cut Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Wells Fargo & Company reduced their price objective on Masimo from $110.00 to $81.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 8th. Needham & Company LLC cut Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Jefferies Financial Group reiterated a “hold” rating and set a $121.00 price target (up from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. Finally, Raymond James cut Masimo from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $121.86.

View Our Latest Report on Masimo

Masimo Trading Up 1.2 %

Masimo stock opened at $134.77 on Monday. The stock has a 50-day moving average of $115.64 and a two-hundred day moving average of $104.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.13 and a current ratio of 2.14. Masimo has a one year low of $75.22 and a one year high of $198.00. The stock has a market cap of $7.12 billion, a PE ratio of 82.18 and a beta of 0.97.

Masimo (NASDAQ:MASIGet Free Report) last released its quarterly earnings results on Tuesday, November 7th. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Masimo had a return on equity of 14.18% and a net margin of 4.19%. The company had revenue of $478.90 million during the quarter, compared to analysts’ expectations of $498.73 million. During the same period last year, the business posted $1.00 earnings per share. The firm’s revenue was down 12.8% compared to the same quarter last year.

Institutional Investors Weigh In On Masimo

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Masimo by 3.0% during the 2nd quarter. BlackRock Inc. now owns 6,120,123 shares of the medical equipment provider’s stock worth $1,007,066,000 after acquiring an additional 178,267 shares in the last quarter. Vanguard Group Inc. raised its stake in Masimo by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock valued at $695,050,000 after acquiring an additional 71,918 shares during the last quarter. State Street Corp raised its stake in Masimo by 1.6% during the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock valued at $251,928,000 after acquiring an additional 27,261 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Masimo during the 3rd quarter valued at approximately $132,699,000. Finally, Eminence Capital LP purchased a new stake in Masimo during the 3rd quarter valued at approximately $90,859,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.

Recommended Stories

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.